Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog



NextPharma is lowering healthcare costs

18 Feb 11

NextPharma is lowering healthcare costs in an environment of continuing Pharma industry restructuring

How to | Get a job in Pharma using

07 Feb 11

If you are new to using to find a new job, you'll soon realise that we have thousands of jobs listed and that they change every day. This means you may initially find the task a bit daunting. However, it’s not really that hard, and with a bit of thought, you will soon be asking why you didn’t do it years ago.
Mike Wood

Patent Box Confirmed

06 Jan 11

At times of global economic downtown, and internal restructuring within firms, risks to innovation arise. And as businesses look for savings, research and development is seldom exempt.
Max Golby

Pharma Advertising and the EU

02 Dec 10

As a result of a vote taken in the European Parliament earlier this week, patients in the European Union will receive improved information on prescription drugs, in addition to being protected from some of the more potentially exploitable clauses of the Commission’s proposed Directive on Information to Patients.
Max Golby

The NHS in the digital age

25 Nov 10

In an age of competition and choice, patient knowledge is paramount. Between 1997 and 2007, the Blair government’s entire programme of public sector reforms were delivered under the banner of ‘Choice and Competition’.
Max Golby

NGP20 Opens Innovation

22 Nov 10

With the global economy remaining stagnant, big pharma companies are keen to develop blockbuster drugs that have a high financial ceiling. Rodger McMillan, VP of R&D at Astra Zeneca has said that “big pharma is a cash-rich industry – it has to be,” namely because of the huge costs in developing new drugs – sometimes as much as $200 million.
Daniel Reinhold-Shor

The Wired & Unemployed Citizenry

18 Nov 10

In the USA alone, when your neighbor is out of work it is a slowdown, when your family member is added it becomes recession and when you too join the same line than it surely becomes a depression. The unofficial employment in USA being claimed at 15-25 percent while the economical turnaround seems a mirage; the closer you get the clearer becomes the reality, nothing but refractions.
Naseem Javed

Quick Look: NICE

16 Nov 10

In many ways, the National Institute for Health and Clinical Excellence (NICE) embodies many of the characteristics that define the NHS. In a system of universal access — and in a world where resources are finite — tough decisions inevitably have to be made. And by taking difficult decisions, particularly in reference to end of life care, NICE attempts to make the most of the drugs budget we do have.
Max Golby

Epratuzumab a new drug in development for SLE shows promising results in EMBLEM study

12 Nov 10

Epratuzumab, a new humanised IgG1 monoclonal antibody that acts on CD22 (a molecule preventing over-activation of the immune system and emergence of auto-immune diseases) has shown promise as a potential treatment of moderate to severe systemic lupus erythematosus (SLE) according to results of a new study EMBLEM.
Olwen Glynn Owen

Imaging Biomarkers

11 Nov 10

Large pharma has been seeking new biomarkers for years – all part of their drug discovery process, but often only as an afterthought in the development process. That’s changed over recent years, but by-and-large the bulk of biomarker work remains in the hands of small -to -medium-sized companies whose focused approach is more attuned to biomarkers being a major element of a final product.
Daniel Reinhold-Shor

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.